Douglas Lane & Associates LLC Grows Stake in Zoetis Inc. $ZTS

Douglas Lane & Associates LLC increased its position in Zoetis Inc. (NYSE:ZTS) by 35.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 306,753 shares of the company’s stock after acquiring an additional 79,906 shares during the period. Douglas Lane & Associates LLC owned about 0.07% of Zoetis worth $44,884,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Savvy Advisors Inc. grew its position in shares of Zoetis by 54.0% during the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after acquiring an additional 1,114 shares during the period. Sound Income Strategies LLC lifted its position in Zoetis by 54.3% during the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after purchasing an additional 152 shares in the last quarter. Canoe Financial LP grew its holdings in Zoetis by 859.0% during the second quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock valued at $2,085,000 after purchasing an additional 11,975 shares during the period. Strs Ohio purchased a new stake in Zoetis in the first quarter worth about $22,891,000. Finally, Chicago Partners Investment Group LLC raised its stake in shares of Zoetis by 67.0% in the second quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after buying an additional 1,961 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. cut their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. UBS Group lowered their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price on the stock. in a research note on Monday, December 15th. Finally, Morgan Stanley set a $160.00 target price on shares of Zoetis in a report on Thursday. Six analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $160.18.

Zoetis Stock Down 0.3%

Shares of ZTS stock opened at $122.34 on Friday. The company’s fifty day simple moving average is $128.86 and its two-hundred day simple moving average is $144.48. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40. The stock has a market cap of $53.91 billion, a P/E ratio of 20.60, a PEG ratio of 2.66 and a beta of 0.97. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be given a dividend of $0.53 per share. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio is currently 33.67%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.